Our core is SIGMOLECS, a proprietary technology combining peptides with hyaluronic acid, acting directly at the site of application. Our portfolio includes medical devices for orthopaedics, sports medicine, rheumatology, pain therapy and rehabilitation, and solutions for aesthetic medicine offering quick post-procedure recovery and long-term optimization of skin’s regenerative capacity. All products for medical promotion are made in EU/Swiss facilities and positioned in the premium segment under strict quality standards.
Contrad Swiss SA

Based in Switzerland, our company pioneers the development of cutting-edge substance-based products within the field of regenerative medicine.
Contrad Swiss is a life sciences company advancing non-invasive solutions in musculoskeletal and aesthetic regenerative medicine.
Activities
Main Activity
Licensing-In (Partial)
Licensing-Out
Development (Partial)
Drug commercialization
Other Activities
Therapeutic Areas
Dermatology
Gynaecology/Women's Health
Infertility (Partial)
Orthopedics
Pain
Rheumatology
Other therapeutic areas
Markets
CH (Partial)
EU Top 5 (Partial)
Rest of Europe (Partial)
LATAM (Partial)
MENA
BRICS
ASEAN
Other market
Drug Stages
Pre-clinical
Clinical Phase I/Phase III
Phase I - Phase III
Registration
Market
Life cycle management
Drug Product Forms
Oral (solid) (Partial)
Oral (liquid) (Partial)
Spray (Partial)
Topical
ODF (Orodispersible Film) (Partial)
Other drug form
Certifications
Swissmedic
GMP
ISO 9001
ISO 13485